Oral Oncology
Volume 46, Issue 4 , Pages e25-e26 , April 2010

Epidermal growth factor receptor (EGFR)-inhibitors, rashes, and survival: Is doxycycline the missing link?

Received 23 January 2010 ,Revised 4 February 2010 ,Accepted 4 February 2010.

References 

  1. Shen LC, Chen YK, Lin LM, Shaw SY. Anti-invasion and anti-tumor growth effect of doxycycline treatment for human oral squamous-cell carcinoma – in vitro and in vivo studies. Oral. 2009;[Epub ahead of print]
  2. Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol. 2009;27:5287–5297
  3. Rosenthal EL, Matrisian LM. Matrix metalloproteases in head and neck cancer. Head Neck. 2006;28:639–648
  4. Onoda T, Ono T, Dhar DK, Yamanoi A, Nagasue N. Tetracycline analogues (doxycycline and COL-3) induce caspase-dependent and -independent apoptosis in human colon cancer cells. Int J Cancer. 2006;118:1309–1315
  5. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11:21–28
  6. Agero AL, Dusza SW, venuto-Andrade C, Busam KJ, Myskowski P, Halpern AC. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol. 2006;55:657–670
  7. Jonker DJ, O’Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, et al. Cetuximab for the treatment of colorectal cancer. New Engl J Med. 2007;357:2040–2048
  8. Saltz L, Kies M, Abbruzzese J, Azarnia N, Needle M. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol. 2003;22:[abstr 817]
  9. BC Cancer Agency. Chemotherapy Protocols – Head and Neck. http://www.bccancer.bc.ca/HPI/ChemotherapyProtocols/HeadnNeck/default.htm. 13-1-2010. Ref Type: Electronic Citation.
  10. Herbst RS, LoRusso PM, Purdom M, Ward D. Dermatologic side effects associated with gefitinib therapy: clinical experience and management. Clin Lung Cancer. 2003;4:366–369
  11. Micantonio T, Fargnoli MC, Ricevuto E, Ficorella C, Marchetti P, Peris K. Efficacy of treatment with tetracyclines to prevent acneiform eruption secondary to cetuximab therapy. Arch Dermatol. 2005;141:1173–1174
  12. Shah NT, Kris MG, Pao W, Tyson LB, Pizzo BM, Heinemann MH, et al. Practical management of patients with non-small-cell lung cancer treated with gefitinib. J Clin Oncol. 2005;23:165–174
  13. Lynch TJ, Kim ES, Eaby B, Garey J, West DP, Lacouture ME. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist. 2007;12:610–621
  14. Saikali Z, Singh G. Doxycycline and other tetracyclines in the treatment of bone metastasis. [Article] Anti-Cancer Drugs. 2003;14:773–778
  15. Wang Y, Shen Y, Li K, Zhang P, Wang G, Gao L, et al. Role of matrix metalloproteinase-9 in lipopolysaccharide-induced mucin production in human airway epithelial cells. Arch Biochem Biophys. 2009;486:111–118
  16. Kim S, Choi JH, Lim HI, Lee SK, Kim WW, Cho S, et al. EGF-induced MMP-9 expression is mediated by the JAK3/ERK pathway, but not by the JAK3/STAT-3 pathway in a SKBR3 breast cancer cell line. Cellul Signal. 2009;21:892–898

☆ In regards to Shen et al., Oral Oncology 2009 Dec 24.

PII: S1368-8375(10)00047-3

doi: 10.1016/j.oraloncology.2010.02.003

Oral Oncology
Volume 46, Issue 4 , Pages e25-e26 , April 2010

Article Tools